Xie Yun, Li Qin, Gao Zhanwei, Sun Jiaming, Li Dong, Harvey Candice, Qu Jiazhi, Snow Sean, Li Qingfeng
Plastic Surgery Department of Shanghai 9th People's Hospital, Shanghai, People's Republic of China.
Plastic Surgery Department of General Hospital of Guangzhou Military Command of PLA, Guangzhou, Guangdong, People's Republic of China.
Clin Cosmet Investig Dermatol. 2022 Feb 16;15:237-245. doi: 10.2147/CCID.S344350. eCollection 2022.
Hyaluronic acid injectable gels are commonly used to treat nasolabial folds (NLFs). We evaluated the safety and effectiveness of VYC-17.5L for correcting NLFs in Chinese subjects.
This prospective, multicenter, double-blind, within-subject‒controlled study randomized adults with moderate-to-severe NLFs to VYC-17.5L treatment (initial and touch-up) in 1 NLF and control (without lidocaine) in the contralateral NLF. Effectiveness endpoints at 6 months included noninferiority of VYC-17.5L to control in NLF Severity Scale response rate (primary endpoint), subject-reported procedural pain (11-point scale), and investigator and subject assessments using the Global Aesthetic Improvement Scale (GAIS).
A total of 175 subjects were included. The primary endpoint was met, with response rates of 84.2% for VYC-17.5L and 82.5% for control. Mean pain scores after initial and touch-up treatments were 2.4 for VYC-17.5L versus 5.2 for control ( < 0.001) and 2.0 versus 3.3 ( < 0.001), respectively. Investigator-rated GAIS scores were 86.5% for VYC-17.5L versus 86.0% for control. There were no between-group differences in subject-rated GAIS scores. Safety profiles were comparable for VYC-17.5L and control.
VYC-17.5L was noninferior to control without lidocaine for correcting moderate-to-severe NLFs in Chinese subjects and was superior to control in reducing procedural pain.
透明质酸注射凝胶常用于治疗鼻唇沟(NLFs)。我们评估了VYC - 17.5L在中国受试者中矫正鼻唇沟的安全性和有效性。
这项前瞻性、多中心、双盲、受试者自身对照研究将患有中度至重度鼻唇沟的成年人随机分为两组,一侧鼻唇沟接受VYC - 17.5L治疗(初始治疗和补打),对侧鼻唇沟接受对照治疗(不含利多卡因)。6个月时的有效性终点包括VYC - 17.5L在鼻唇沟严重程度量表反应率方面不劣于对照(主要终点)、受试者报告的操作疼痛(11分制),以及研究者和受试者使用全球美学改善量表(GAIS)进行的评估。
共纳入175名受试者。达到了主要终点,VYC - 17.5L的反应率为84.2%,对照为82.5%。初始治疗和补打治疗后的平均疼痛评分,VYC - 17.5L分别为2.4,对照为5.2(<0.001),以及2.0和3.3(<0.001)。研究者评定的GAIS评分,VYC - 17.5L为86.5%,对照为86.0%。受试者评定的GAIS评分在组间无差异。VYC - 17.5L和对照的安全性概况相当。
在矫正中国受试者的中度至重度鼻唇沟方面,VYC - 17.5L不劣于不含利多卡因的对照,且在减轻操作疼痛方面优于对照。